Results 111 to 120 of about 3,096 (189)

Enfortumab Vedotin [PDF]

, 2020
openaire   +1 more source

Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study [PDF]

\ua9 2025 by American Society of Clinical Oncology.PURPOSE Our investigation assessed the impact of geographical disparities in the treatment of patients with advanced urothelial cancer (aUC) included in the international, real-world ARON-2 trial ...
Bamias A, Bellmunt J, Bourlon MT, Buti S, Buttner T, Calabro F, Epstein I, Fiala O, Giannatempo P, Grande E, Gupta S, Kanesvaran R, Marques Monteiro FSM, Massari F, Molina-Cerrillo J, Myint ZW, Park SH, Porta C, Rescigno P, Rizzo M, Santini D, Santoni M, Soares A, Takeshita H, Zakopoulou R   +24 more
core  

Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives [PDF]

Antibody-drug conjugates have emerged as a promising cancer treatment, combining targeted delivery of cytotoxic agents with the specificity of monoclonal antibodies. Despite their potential, ADCs face limitations such as resistance and off-target effects.
Baoxin Shang, Jianbao Gong, Jianqiao Cui, Kai Tang, Lin Quan, Nuan Feng, Qingkun Han, Quanbin Zhang, Xianglong Shi, Xuwen Li, Xuwen Li, Yijing Li   +11 more
core   +1 more source

Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer

Therapeutic Advances in Urology
Antibody-drug conjugates and bicycle toxin conjugates represent a tremendous advance in drug delivery technology and have shown great promise in the treatment of urothelial cancer.
Chaim Domb, Jorge A. Garcia, Pedro C. Barata, Prateek Mendiratta, Santosh Rao, Jason R. Brown   +5 more
doaj   +1 more source

Cutaneous drug reaction induced by enfortumab-vedotin. [PDF]

CMAJ
Gretschel L, Wetzel E, Mittank-Weidner T.   +2 more
europepmc   +1 more source

Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation. [PDF]

J Int Med Res
Chan KH, Cen P, Shu T, Canfield S, Zhao H, Gonzalez A, Rowe J, Tammisetti V, Ayoub H, Blanco A, Amsbaugh M, Tannir N.   +11 more
europepmc   +1 more source

First-Line Enfortumab Vedotin Plus Pembrolizumab in Platinum-Ineligible Urothelial Carcinoma: A Three-Case Series. [PDF]

Cureus
Igarashi D, Kaneko G, Takamatsu K, Shirotake S, Oyama M.   +4 more
europepmc   +1 more source

First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study. [PDF]

Front Public Health
Ying H, Fu B.
europepmc   +1 more source

Optimizing enfortumab vedotin plus pembrolizumab therapy. [PDF]

Oncotarget
Karam EA, Céline YC, Prince G, Attieh F, Kourie HR, Kattan J, Nemer E.   +6 more
europepmc   +1 more source

Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer [PDF]

Catalano, Martina, Guarino, Adriana, Roviello, Giandomenico   +2 more
core   +1 more source